

Studies concerning the electrophilic amino-alkene cyclisation for the synthesis of bicyclic amines†

Johannes E. M. N. Klein, Helge Müller-Bunz and Paul Evans*

Received 4th November 2008, Accepted 4th December 2008

First published as an Advance Article on the web 23rd January 2009

DOI: 10.1039/b819610a

The bromination of a series of cyclohexenyl substituted secondary amines **1a-i** has been investigated using Br₂, PHT and NBS. In the case of Br₂ and NBS the secondary amines preferentially undergo *N*-bromination. In contrast, PHT cleanly affords the products of alkene dibromination. In the case of Br₂ the *N*-bromo species then give the products of alkene dibromination, albeit less efficiently. On subsequent treatment with K₂CO₃ these dibromides form the corresponding hexahydroindoles **2a-h** and octahydroquinoline **2i**. The presence of an *N*-substituent bearing a stereogenic centre (**1h** and **1i**) was studied and the products **2h** and **2i** were isolated with no diastereoselectivity. When NBS was used a novel cyclisation, forming bromo-substituted octahydroindoles **9a,b** and **d**, was observed. In relation to this sequence it was shown that these products were not intermediates in the former Br₂/PHT processes and that the reaction only proceeded in the presence of the succinimide by-product of *N*-bromination.

Introduction

There have been several recent reports concerning the reaction of amines with alkenes not possessing electron-withdrawing groups in the presence of various catalysts and mediators. In these examples alkene functionalisation affords alkyl amino compounds.¹ However, arguably a more synthetically useful reaction is the halo-amino functionalisation of alkenes since in this instance both alkenyl carbon atoms become functionalised, thereby enabling further derivatisation. Several examples of this class of reaction have been reported using various substrates and halogen sources.² In relation to this general reaction type an efficient sequence caught our attention in which the cyclic alkene **1** undergoes a 2-step intramolecular conversion into **2** following its initial reaction with acid washed bromine and subsequent treatment with K₂CO₃ (Scheme 1).³ The authors speculate that this trans-


formation proceeds *via* initial alkene dibromination followed by a regioselective base mediated elimination and S_N2' cyclisation sequence⁴ affording the products **2** of formal C–H activation.‡

Mechanistically, although this seems reasonable, it does not adequately account for the reported observation that when R represents α -methylbenzyl the bicyclic product **2** is isolated in high diastereomeric excess (>95% d.e.).³ Since the stereogenic centre is, in this instance, remote from the double bond it would appear remarkable that this group would dictate and control the stereofacial sense of the intermolecular bromonium ion formation required for the generation of **2** as a single diastereoisomer. One possible alternative mechanistic explanation for this reported diastereocontrol is that the secondary amine is directly involved in the activation of the trisubstituted alkene by initial *N*-bromination to form **5**. In turn it may be speculated that this *N*-bromo species **5** might react with the alkene in an intramolecular sense *via* a polar transition state of the type **6** or **7**. In relation to this suggestion numerous examples do exist concerning the formation of *N*-halo


Centre for Synthesis and Chemical Biology, School of Chemistry and Chemical Biology, University College Dublin, Dublin 4, Ireland. E-mail: paul.evans@ucd.ie

† Electronic supplementary information (ESI) available: General procedures for the preparation of secondary amines **1a–1f**, procedures for the synthesis of amines **1g–1i**, experimental details for the X-ray crystallography and X-ray structures of compounds **2a**, **1b-HBr** and **S6**. CCDC reference numbers 707945–707951. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/b819610a

‡ Substituted cyclopentenyl and cyclohexenyl systems were not employed in this study, consequently it is not possible to state unequivocally whether this process is S_N2' rather than S_N2, although the pathway followed is crucial since the different modes of substitution lead to diastereoisomeric products when R contains a stereogenic centre.⁴ The direct S_N2 displacement of **3** appears to be precluded based on stereoelectronic arguments.



Scheme 1 The bromo-amino cyclisation of alkenyl secondary amines **1**.



Scheme 2 Synthesis of hexahydroindoles **2a–g** (X = Br, or H).

compounds from electron rich amines.^{5–8} Typically such species possess limited stability and their reactivity and stability has been investigated both from a theoretical and practical standpoint. For example, their treatment with base leads to dehydrohalogenation and formation of an imine.⁵ A synthetic application of this sequence has been used in order to achieve α -amino functionalisation as applied to the synthesis of perhydrohistrionicotxin.⁶ Additionally, several reports indicate that this general class of compound may effectively act as halogenating agents (*i.e.* **6**)⁷ and the possibility that **5** might, alternatively, act as an electrophilic source of nitrogen was also considered.⁸ Examples involving the bromination, or chlorination of double bonds in the presence of basic amino functionality (*i.e.* non-protected) are scarce.⁹

Results and discussion

Intrigued by the possibility that the functionalisation of this type of alkene (Scheme 1) might proceed *via* initial *N*-bromination followed by intramolecular bromonium ion formation (**6**), or direct cyclisation (**7**) our first approaches focussed on the use of the *N*-benzylamine derivative **1a** § following the previously described procedure.³ Exposure of **1a** to Br₂ (1.2 equiv.) at –78 °C for 0.5 hours in dichloromethane, followed by treatment of the material thus obtained with K₂CO₃ (3 equiv.) in acetone at 50 °C, gave *N*-benzyl hexahydroindole **2a** reproducibly in 50–61% yield (see Scheme 2, Entry 1, Method A).

Although the desired product **2a** was obtained, several experimental observations gave further insight into the possible pathway of this reaction. Crude proton NMR spectroscopy after the initial treatment of **1a** with 1.0 equivalent of bromine (CDCl₃, rt, after 5 minutes) indicated significant preservation of the double bond (*ca.* 50%), which was attributed to the competitive formation of an *N*-bromoammonium compound of type **5a** (see also Scheme 5). ¶ Furthermore, the formation of benzaldehyde was observed,

§ For the synthesis of secondary amines **1a–g** and the X-ray crystallographic structure of **2a** see ESI.†


¶ Treatment of **1a** with 0.5 equiv., 1 equiv. and 2 equiv. of Br₂ indicated that complete alkenyl bromination only occurred using 2 equivalents of Br₂, while the use of sub-stoichiometric or stoichiometric amounts resulted in selective, initial *N*-bromination leading to **5a**. Evidence for this was indicated by a significant shift of the benzylic proton signal observed by

also indicating a pathway involving *N*-bromination followed by elimination and subsequent hydrolysis of the so-formed imine. Although this evidence combined to suggest that mechanisms involving species such as **6** or **7** may indeed operate, another possibility is that the *N*-bromo species **5** releases molecular bromine, which over time leads to the formation of the dibromide (of the type **3**). Additional secondary amines **1b** (Entry 2, Method A), **1e** (Entry 5, Method A) provided the corresponding hexahydroindoles **2b** and **2e** in similarly reasonable yields following their respective treatment with bromine and subsequently K₂CO₃.

While the use of a conventional protecting group to obviate the apparently rapid *N*-halogenation pathway and achieve clean bromination would only serve to add steps to a synthesis, the use of hydrotribromide was attempted. In this instance it was felt that protonation (*i.e.* temporary protection) of the amine would effectively prevent *N*-bromination, ultimately leading to a cleaner process.¹⁰ Additionally, ammonium ion formation would preclude the direct intermediacy of *N*-bromo species **5** in the reaction mechanism. In the presence of the commercially available pyrrolidone hydrotribromide (PHT)¹¹ smooth alkenyl dibromination could be carried out at room temperature in dichloromethane. For example, **1a** was converted into the dibromoammonium species **3a** (as its HBr salt), which was characterised by NMR spectroscopy and mass spectrometry. The dibromide **3a** was then successfully subjected to the second cyclisation step as before. Thus, **2a** was isolated following purification by flash column chromatography in 85% yield (Scheme 2, Entry 1). Notably, following this modified reaction procedure (Method B) significantly cleaner reactions were observed for all the secondary amine substrates studied (**1b–g**) and the hexahydroindole adducts (**2b–g**) were isolated in consistently higher yields than the sequence effected using molecular bromine (Method A). In the case of **2f**, no products of electrophilic aromatic substitution were detected.

With this information in hand we then investigated the diastereoselective cyclisation of α -methylbenzylamine containing substrates ($\pm$)-**1h** and (+)-**1i** (Scheme 3).§ In both cases, using either molecular bromine or the modified PHT conditions, the

NMR spectroscopy. Compound **5a** was also prepared using NBS and although it proved to be unstable, proton NMR spectra were comparable (Scheme 5).



Method A: (a) Br₂ (1.2 equiv.), CH₂Cl₂, -78°C, 20 min.; then (b) K₂CO₃ (3 equiv.), acetone, 50°C, 5–8 days;

Method B: (a) PHT (1 equiv.), CH₂Cl₂, rt, 15 min.; then (b) K₂CO₃ (3 equiv.), acetone, 50°C, 5–8 days;

Scheme 3 Investigation of diastereoselective approaches to hexahydroindole **2h** and octahydroquinoline **2i**.

corresponding hexahydroindole **2h** and octahydroquinoline **2i** were formed in moderate to good yield. However, using either Br₂ or PHT it was immediately evident from inspection of the crude proton NMR spectra that these reactions *did not* proceed in a diastereoselective fashion. Furthermore, in both cases, using either reaction conditions, formation of an approximately 1:1 mixture of diastereoisomers was evident. In the case of the racemic hexahydroindole **2h**, in our hands, the diastereoisomers proved only partially separable by flash column chromatography. The slightly faster moving diastereoisomer was separated in a small amount and its spectroscopic data proved equivalent to that reported.^{3a} This material crystallised as its HCl salt and an X-ray structure was obtained, thereby demonstrating its relative stereochemistry (Fig. 1).¹² Using Br₂ (2.2 equiv.) the identity of the intermediate dibromide **3h** was subsequently investigated. Crucially, 2.2 equivalents of Br₂ were required for complete conversion and after work-up we assume that degradation of any *N*-bromo species occurs (see also above and the footnote[¶]). Although the proton NMR spectrum was not helpful, splitting, attributed to the presence of two diastereomeric species (*S*,S*,R**)-**3h** and (*R*,R*,R**)-**3h**, was detected in the carbon NMR spectrum. The homologated α-methylbenzylamine (+)-**1i** was also prepared for comparison and although the cyclisation proved to be slower than in the previous case, octahydroquinoline **2i** successfully formed as a mixture of two diastereoisomers.

In this instance the diastereoisomers proved to be readily separable by flash column chromatography enabling their complete spectroscopic characterisation in this enantiopure series. The slower moving diastereoisomer proved to be crystalline as its HCl salt (Fig. 1) and the relative stereochemistry of both diastereoisomers was thus deduced.¹³ As observed for **2h**, spectroscopic data for the faster moving diastereoisomer (*R,R*)-**2i** matched that reported previously.^{3a}

Clearly based on these results no difference in diastereoselectivity was observed between the different methods for bromination, which serves to suggest that, in our hands at least, this reaction does not proceed *via* the type of discrete intramolecular intermediate proposed in Scheme 1, which might be able to






Fig. 1 X-ray crystallographic structures of (*R*,R**)-**2h**·HCl¹² and (*S,R*)-**2i**·HCl¹³ (thermal ellipsoids drawn at the 15% probability level). Note that for **2h**·HCl the co-crystallised H₂O is not shown for clarity.

efficiently relay stereochemical information from the chiral centre attached to the amine to the alkene. It seems likely, therefore, that the diastereomeric mixture of dibromides **3h** and **3i** generate a diastereomeric mixture of **8** which then undergoes cyclisation to **2h** and **2i**. Evidence for the intermediacy of **8** was observed on storage of the intermediate dibromide **3h** in CDCl₃; within 48 hours a characteristic alkenyl signal in its ¹H-NMR spectrum developed, which was assigned to allylic bromide **8** (5.70 ppm).

Nevertheless, we decided to further investigate the formation of *N*-bromoamino species of the type **5** and attempted to study the reaction and hoped for cyclisation of benzylamine **1a** using

Scheme 4 NBS mediated cyclisation of cyclohexenyl amines **1a**, **1b** and **1d**.


N-bromosuccinimide (NBS). Potentially the type of tertiary amine product **9** of this reaction might be formed according to hypothetical transition states **6**, or **7** (Scheme 1). Regioselective base mediated elimination of such a species might then be expected to generate the final unsaturated products **2**. Treatment of **1a** with 1 equivalent of NBS in dichloromethane resulted in the rapid consumption of the starting material and the formation of a significantly less-polar compound. If the reaction period was prolonged and the temperature raised to 40 °C the bicyclic adduct **9a** was indeed obtained (32%) following purification by flash column chromatography (Scheme 4). Identical results were observed for alternative starting materials **1b** and **1d**. Even though the yields for this process were low the adducts formed as single diastereoisomers and the relative stereochemistry was elucidated by X-ray crystallography after formation of **9a**·HCl (Fig. 2).¹⁴

Fig. 2 X-ray crystallographic structure of **9a**·HCl (thermal ellipsoids drawn at the 50% probability level).¹⁴

Although the X-ray structure of **9a** indicated that the only anti-periplanar hydrogen–bromine relationship would give rise to **2a**, treatment with K₂CO₃ in acetone at 50 °C (comparable to the second step in the conversion of **1** to **2**) did not lead to elimination, which served to indicate that **9** cannot be a direct intermediate in this cyclisation process.

During attempts to further optimise this reaction we realised that on altering the solvent from dichloromethane to diethyl ether cyclisation was not observed. The sole product from this reaction was the *N*-bromo compound **5a** that could be isolated on filtration (Scheme 5). However, this species proved to be only moderately stable and over time underwent decomposition forming the hydrobromide salt of **1a**. When **5a** was prepared using 1.2 equivalents of bromine, limited stability was also observed (see discussion above).

Generally, **9a,b** and **d** proved to be stable enough to enable characterisation but, in the amino form, were found to decompose over time. We finally attempted to investigate the corresponding cyclisation using **1h**, hoping to observe a stereoselective process. However, in this instance we believe that, again, a mixture of adducts was formed in low yield although complete characterisa-

Scheme 5 Selective *N*-halogenation of amino alkenes **1a** and **1b**.



tion proved not to be possible since one of these diastereoisomers proved to decompose to several unidentified products.

Since these results suggested the involvement of an *N*-bromo species in the formation of **9** we attempted the cyclisation of *N*-bromo compound **5a** (after the removal of succinimide) under reflux conditions as before. This, however, did not lead to formation of the cyclised product. In contrast, when **5a** was prepared in diethyl ether and the solvent was changed to dichloromethane without the prior removal of succinimide by filtration, cyclisation to **9a** was observed in comparable yield (27%). This observation serves to suggest that either, under these conditions NBS is reformed reversibly, or that protonation¹⁵ of the *N*-bromo species **5a** is a crucial process in the intramolecular formation of **9a**.

The corresponding *N*-chloro species proved to be more stable than their bromine counterparts and **10a** and **10b** were isolated in good yield and fully characterised spectroscopically. Contrasting reactivity was also observed for **10a**; this species did not form bicycle **11a** under conditions identical to those that proved successful for the bromide **9a**. Instead **10a** was recovered unchanged, an observation that again reflects the enhanced stability of the *N*-chloro series.

N-Benzyl bicyclic adducts **2a** and **2g** were subjected to standard catalytic hydrogenation under acidic conditions, leading to both debenzilation and hydrogenation of the double bond. The secondary amino compounds were then converted into their toluene sulfonamides **12a** and **12g** to simplify purification (Scheme 6). A drastic difference was observed in terms of the diastereoselectivity for the alkenyl reduction process: whilst **2a** gave **12a** as a single diastereoisomer **2g** gave **12g** as a mixture of diastereoisomers (ca. 1:1).¹⁶

The relative stereochemistry of **12a** was uncovered by X-ray crystallography (Fig. 3)¹⁷ which provides relevant information for previous studies concerning this compound in which the relative stereochemistry was not definitively assigned.¹⁸ Similarly, the hydrogenation of **9a** was investigated in order to remove the benzyl group and although this process proceeded in only low yield (23%) the expected product **13** was obtained with the tertiary bromide intact.

Scheme 6 Debenzylation of bicycles **2a**, **2g** and **9a**.Fig. 3 X-ray crystallographic structure of **12a** (thermal ellipsoids drawn at the 50% probability level).¹⁷

Conclusion

In summary, while the results discussed served to demonstrate that the amino alkenes employed in this study show a strong tendency to form *N*-halo species more rapidly than reaction at the alkene (when treated with Br₂ or NBS), we cannot confirm the direct involvement of such species in the cyclisation step leading to hexahydroindoles. As such it seems that this *N*-halogenation process may be viewed as a side reaction rather than a productive element of the overall reaction pathway. The diastereoselective formation of hexahydroindoles and octahydroquinolines has been investigated following the claim that high diastereoselectivity may be achieved.³ However, using an α -methylbenzyl substituent as a directing group we were unable to reproduce the reported results, suggesting that this work should be viewed with caution. In relation to this sequence we have demonstrated that PHT may be used to brominate a double bond in the presence of an amine featuring temporary protection through protonation, and in doing so have improved the overall yield for the aminocyclisation procedure. Finally, differences in the diastereoselectivity of the catalytic hydrogenation of hexahydroindoles and octahydroquinolines were noticed.

Experimental

Reactions with anhydrous solvents were carried out under an atmosphere of N₂. Glassware was either dried in an oven or by heat-gun before use, assembled hot and cooled to room temperature under a stream of N₂. Anhydrous dichloromethane (CH₂Cl₂) was distilled from CaH₂ prior to use. Reagents were purchased from Acros, or Aldrich, and used without further purification. Thin layer chromatography (TLC) was carried out on Merck silica gel aluminum sheets (60 F254). UV light and a KMnO₄ solution were used as visualising agents. Merck silica gel (60 Å, 0.040–0.063 mm) was used for flash column chromatography. Proton NMR spectra were recorded on a Varian 300 MHz, 400 MHz, 500 MHz or 600 MHz spectrometer and calibrated using the residual non-deuterated solvent signal. IR spectra were recorded on a

Varian 3100 FT-IR spectrometer. High Resolution Mass Spectra (HRMS) were recorded using a Waters Corp, Micromass LCT, Electrospray Ionization (ESI) spectrometer. Melting points were determined in an open capillary on a Gallenkamp melting point apparatus and are uncorrected. The amine-hydrochloride salts were prepared as follows: the amine was dissolved in Et₂O/pentane (*ca.* 25 mg/ml) and HCl gas (generated from solid NH₄Cl by dropwise addition of conc. H₂SO₄) was bubbled through the solution *via* a Teflon cannula. The resultant precipitate was filtered, dried under vacuum and the hydrochloride salts were recrystallised from a suitable solvent. For the syntheses of secondary amines **1a-i** see ESI.†

General procedure for the amino cyclisation using molecular bromine, Method A^{3a,b}

The appropriate secondary amine was dissolved in anhydrous dichloromethane (10 ml/mmol) under an atmosphere of N₂. The solution was cooled to –78 °C before Br₂ (1.2 equiv.) was added as a solution in anhydrous dichloromethane (1 ml/mmol) over a period of 15 min. The solution was stirred for a further 15 min at low temperature. Solvent was removed under reduced pressure and the residue suspended in acetone (10 ml/mmol) and K₂CO₃ (3 equiv.) was added. The suspension was heated to 50 °C for 72 h before the solvent was removed under reduced pressure and the residue partitioned between H₂O (10 ml/mmol) and dichloromethane (20 ml/mmol). The aqueous layer was further extracted with dichloromethane (2 × 10 ml/mmol) and the combined organic extracts dried over Na₂SO₄. After filtration the solvent was removed under reduced pressure and the crude products were purified by column chromatography as indicated below.

General procedure for the amino cyclisation using pyrrolidone hydrotribromide, (PHT), Method B

The secondary amine was dissolved in dichloromethane (10 ml/mmol) under air. To the solution was added PHT (1 equiv.) in one portion. The solution was stirred for a total of 15 min and the solvent subsequently removed under reduced pressure. The residue was dissolved in acetone (10 ml/mmol) and K₂CO₃ (3 equiv.) was added in one portion. The suspension was heated to 50 °C for 67–70 h before the solvent was removed under reduced pressure and the residue partitioned between H₂O (10 ml/mmol) and dichloromethane (20 ml/mmol). The aqueous layer was re-extracted with dichloromethane (2 × 10 ml/mmol). The combined organic layers were dried over Na₂SO₄ and the solvent removed under reduced pressure. The crude products were purified by column chromatography as indicated below.

1-Benzyl-2,3,5,6,7,7a-hexahydro-1H-indole (2a)

The *title compound* was purified by column chromatography (EtOAc-cyclohexane; 1:12) which gave **2a** as a yellow oil [Method A: 62%; Method B: 85%]. The purified product solidified upon storage in the fridge to give X-ray quality crystals (see ESI†). M.pt. 28–30 °C; R_f = 0.45 (EtOAc); $^1\text{H-NMR}$ (500 MHz, CDCl_3) δ (ppm) 7.33 (d, J = 7.5 Hz, 2H) 7.29 (t, J = 7.5 Hz, 2H) 7.22 (t, J = 7.5 Hz, 1H) 5.43 (bs, 1H) 4.06 (d, J = 13.0 Hz, 1H) 3.22 (d, J = 13.0 Hz, 1H) 2.92–2.97 (m, 1H) 2.57–2.63 (m, 1H) 2.32–2.38 (m, 2H) 2.02–2.13 (m, 4H) 1.81–1.88 (m, 1H) 1.43–1.54 (m, 1H) 1.54 (q, J = 12.0 Hz, 1H); $^{13}\text{C-NMR}$ (125.6 MHz, CDCl_3) δ (ppm) 140.3 (C) 138.9 (C) 129.1 (CH) 128.1 (CH) 126.8 (CH) 118.5 (CH) 64.4 (CH) 58.8 (CH₂) 52.0 (CH₂) 28.1 (CH₂) 27.9 (CH₂) 25.1 (CH₂) 20.5 (CH₂); IR (neat) 3377, 3030, 2927, 2851, 2785, 2723, 2348, 1651, 1609 cm^{-1} ; HRMS (ES^+) calcd. for $[\text{C}_{15}\text{H}_{20}\text{N}]^+$ 214.1596; found 214.1586.

1-(4-Methoxybenzyl)-2,3,5,6,7,7a-hexahydro-1H-indole (2b)

The *title compound* was purified by flash column chromatography (EtOAc-cyclohexane; 1:7) to give **2b** as a clear oil [Method A: 53%; Method B: 88%]. R_f = 0.30 (EtOAc); $^1\text{H-NMR}$ (500 MHz, CDCl_3) δ (ppm) 7.24 (d, J = 8.5 Hz, 2H) 6.83 (d, J = 8.5 Hz, 2H) 5.42 (bs, 1H) 3.99 (d, J = 12.7 Hz, 1H) 3.79 (s, 3H) 3.17 (d, J = 12.7 Hz, 1H) 2.90–2.95 (m, 1H) 2.54–2.60 (m, 1H) 2.31–2.37 (m, 2H) 2.02–2.13 (m, 4H) 1.81–1.87 (m, 1H) 1.42–1.53 (m, 1H) 1.12–1.21 (m, 1H); $^{13}\text{C-NMR}$ (125.6 MHz, CDCl_3) δ (ppm) 158.6 (C) 140.4 (C) 131.0 (C) 130.2 (CH) 118.5 (CH) 113.5 (CH) 64.3 (CH) 58.1 (CH₂) 55.2 (CH₃) 51.9 (CH₂) 28.1 (CH₂) 27.9 (CH₂) 25.1 (CH₂) 20.5 (CH₂); IR (neat) 3061, 2998, 2930, 2834, 2780, 2718, 2542, 2483, 2278, 2065, 1995, 1882, 1756, 1692, 1612, 1586, 1513 cm^{-1} ; HRMS (ES^+) calcd. for $[\text{C}_{16}\text{H}_{22}\text{NO}]^+$ 244.1701; found 244.1693.

1-(2-Methoxybenzyl)-2,3,5,6,7,7a-hexahydro-1H-indole (2c)

Purification by column chromatography (EtOAc-cyclohexane; 1:7) gave the *title compound* **2c** as a clear yellow oil [Method B: 88% yield]. R_f = 0.40 (EtOAc); $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ (ppm) 7.36 (dd, J = 1.5 Hz, J = 7.5 Hz, 1H) 7.22 (dt, J = 1.5 Hz, J = 8.0 Hz, 1H) 6.91 (t, J = 7.5 Hz, 1H) 6.81 (d, J = 8.0, 1H) 5.42 (bs, 1H) 4.04 (d, J = 13.5 Hz, 1H) 3.83 (s, 3H) 3.40 (d, J = 13.5 Hz, 1H) 3.03–3.08 (m, 1H) 2.62–2.69 (m, 1H) 2.34–2.40 (m, 2H) 2.12–2.22 (m, 2H) 2.03–2.08 (m, 2H) 1.83–1.90 (m, 1H) 1.44–1.56 (m, 1H) 1.14–1.24 (m, 1H); $^{13}\text{C-NMR}$ (100.5 MHz, CDCl_3) δ (ppm) 157.6 (C) 140.6 (C) 130.8 (CH) 127.9 (CH) 127.1 (C) 120.2 (CH) 118.4 (CH) 110.3 (CH) 64.2 (CH) 55.3 (CH₃) 52.0 (CH₂) 51.8 (CH₂) 28.1 (CH₂) 28.0 (CH₂) 25.2 (CH₂) 20.6 (CH₂); IR (neat) 3441, 3000, 2930 2857, 2835, 2789, 2721, 1690, 1601, 1589 cm^{-1} ; HRMS (ES^+) calcd. for $[\text{C}_{16}\text{H}_{22}\text{NO}]^+$ 244.1701; found 244.1700.

1-(2,4,6-Trimethylbenzyl)-2,3,5,6,7,7a-hexahydro-1H-indole (2d)

The *title compound* was purified by flash column chromatography (EtOAc-cyclohexane; 1:19) to give **2d** as a white solid [Method B: 85%]. M.pt. 35–37 °C; R_f = 0.55 (EtOAc); $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ (ppm) 6.83 (s, 2H) 5.40 (bs, 1H) 3.91 (d, J = 12.5 Hz, 1H) 3.33 (d, J = 12.5 Hz, 1H) 2.81–2.81 (m, 1H) 2.59–2.66 (m,

1H) 2.39 (s, 6H) 2.27 (s, 3H) 2.23–2.36 (m, 2H) 2.11–2.22 (m, 2H) 2.03–2.10 (m, 2H) 1.82–1.91 (m, 1H) 1.45–1.60 (m, 1H) 1.16–1.26 (m, 1H); $^{13}\text{C-NMR}$ (100.5 MHz, CDCl_3) δ (ppm) 141.3 (C) 137.6 (C) 136.0 (C) 132.8 (C) 128.9 (CH) 117.8 (CH) 65.4 (CH) 52.0 (CH₂) 51.8 (CH₂) 28.2 (CH₂) 27.9 (CH₂) 25.2 (CH₂) 20.9 (CH₃) 20.6 (CH₂) 20.3 (CH₃); IR (neat) 3441, 3004, 2923, 2836, 2782, 2716, 1689, 1613, 1580 cm^{-1} ; HRMS (ES^+) calcd. for $[\text{C}_{18}\text{H}_{26}\text{N}]^+$ 256.2065; found 256.2072.

1-(2-Bromo-4,5-dimethoxybenzyl)-2,3,5,6,7,7a-hexahydro-1H-indole (2e)

Purification by flash column chromatography (EtOAc-cyclohexane; 1:12) gave **2e** as a light tan solid [Method A: 63%; Method B: 77%]. M.pt. 84–86 °C; R_f = 0.40 (EtOAc); $^1\text{H-NMR}$ (500 MHz, CDCl_3) δ (ppm) 7.03 (s, 1H) 6.99 (s, 1H) 5.44 (bs, 1H) 3.99 (d, J = 13.5 Hz, 1H) 3.86 (s, 3H) 3.85 (s, 3H) 3.40 (d, J = 13.5 Hz, 1H) 3.00–3.05 (m, 1H) 2.67–2.73 (m, 1H) 2.35–2.43 (m, 2H) 2.19 (q, J = 9.0 Hz, 1H) 2.07–2.13 (m, 1H) 2.02–2.07 (m, 2H) 1.82–1.88 (m, 1H) 1.44–1.55 (m, 1H) 1.13–1.23 (m, 1H); $^{13}\text{C-NMR}$ (125.6 MHz, CDCl_3) δ (ppm) 148.4 (C) 148.3 (C) 140.3 (C) 130.4 (C) 118.5 (CH) 115.2 (CH) 114.0 (C) 113.6 (CH) 64.7 (CH) 57.6 (CH₂) 56.1 (CH₃) 56.0 (CH₃) 52.3 (CH₂) 28.1 (CH₂) 28.0 (CH₂) 25.0 (CH₂) 20.4 (CH₂); IR (CH_2Cl_2) 3376, 3000, 2932, 2936, 2796, 1648, 1603, 1506 cm^{-1} ; HRMS (ES^+) calcd. for $[\text{C}_{17}\text{H}_{23}\text{NO}_2\text{Br}]^+$ 352.0912; found 352.0918.

1-(Furan-2-ylmethyl)-2,3,5,6,7,7a-hexahydro-1H-indole (2f)^{3a}

Compound **2f** was purified by column chromatography (EtOAc-cyclohexane; 1:19) to give a yellow oil [Method A: 65%;³ Method B: 74%]. R_f = 0.60 (EtOAc); $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ (ppm) 7.35–7.36 (m, 1H) 6.30 (dd, J = 2.0 Hz, J = 3.0 Hz, 1H) 6.19 (d, J = 3.0 Hz, 1H) 5.41 (bs, 1H) 3.94 (d, J = 14.0 Hz, 1H) 3.46 (d, J = 14.0 Hz, 1H) 3.01–3.06 (m, 1H) 2.53–2.60 (m, 1H) 2.34–2.42 (m, 2H) 2.21–2.28 (m, 1H) 1.99–2.10 (m, 3H) 1.80–1.87 (m, 1H) 1.40–1.52 (m, 1H) 1.10–1.20 (m, 1H); $^{13}\text{C-NMR}$ (100.5 MHz, CDCl_3) δ (ppm) 152.4 (C) 141.8 (CH) 140.0 (C) 118.6 (CH) 110.0 (CH) 108.0 (CH) 63.5 (CH) 51.9 (CH₂) 49.8 (CH₂) 27.9 (CH₂) 27.7 (CH₂) 25.0 (CH₂) 20.5 (CH₂); IR (neat) 3437, 3114, 3062, 2922, 2858, 2788, 2660, 1642, 1599, 1504 cm^{-1} ; HRMS (ES^+) calcd. for $[\text{C}_{13}\text{H}_{18}\text{NO}]^+$ 204.1388; found 204.1380.

1-Benzyl-1,2,3,4,6,7,8,8a-octahydroquinoline (2g)

The *title compound* was isolated following purification by flash column chromatography (EtOAc-cyclohexane; 2:23) as a clear oil [Method B: 62%]. R_f = 0.30 (EtOAc); $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ (ppm) 7.27–7.33 (m, 4H) 7.19–7.24 (m, 1H) 5.51 (bs, 1H) 4.16 (d, J = 13.5 Hz, 1H) 3.11 (d, J = 13.5 Hz, 1H) 2.82–2.88 (m, 1H) 2.7–2.76 (m, 1H) 2.19–2.32 (m, 2H) 1.90–2.12 (m, 4H) 1.73–1.83 (m, 1H) 1.42–1.60 (m, 4H); $^{13}\text{C-NMR}$ (100.5 MHz, CDCl_3) δ (ppm) 139.6 (C) 136.8 (C) 129.2 (CH) 128.1 (CH) 126.7 (CH) 122.6 (CH) 61.0 (CH) 58.3 (CH₂) 53.3 (CH₂) 34.5 (CH₂) 29.6 (CH₂) 26.3 (CH₂) 25.5 (CH₂) 21.6 (CH₂); IR (neat) 3084, 3061, 3026, 2931, 2856, 2836, 2784, 2746, 2724, 2651, 1602 cm^{-1} ; HRMS (ES^+) calcd. for $[\text{C}_{16}\text{H}_{22}\text{N}]^+$ 228.1752; found 228.1743.

1-((1-Phenylethyl)-2,3,5,6,7,7a-hexahydro-1H-indole (2h)

Following the general procedures **2h** was prepared albeit after 5 d for the second, K_2CO_3 operation [Method A: 51%; Method B: 67% as a 1:1 mixture of diastereoisomers (determined by 1H -NMR spectroscopy of crude reaction products)]. The two diastereoisomers proved to be very difficult to separate by flash column chromatography. However, partial purification proved to be possible (EtOAc-cHex; 2:23) enabling characterisation of both diastereoisomers. The relative stereochemistry of the faster moving diastereoisomer was determined by X-ray crystallography after formation of the hydrochloride salt. X-ray quality crystals were obtained by slow evaporation from EtOAc. (**R***)-1-((**R***)-1-Phenylethyl)-2,3,5,6,7,7a-hexahydro-1H-indole (**2h**):^{3a} viscous oil; R_f = 0.20 (EtOAc); 1H -NMR (400 MHz, $CDCl_3$) δ (ppm) 7.37 (d, J = 7.5 Hz, 2H) 7.28 (t, J = 7.5 Hz, 2H) 7.21 (t, J = 7.5 Hz, 1H) 5.39 (bs, 1H) 3.64 (q, J = 6.5 Hz, 1H) 3.02–3.07 (m, 1H) 2.68–2.74 (m, 1H) 2.31–2.42 (m, 3H) 1.94 (bs, 2H) 1.57–1.66 (m, 1H) 1.39 (d, J = 6.5 Hz, 3H) 1.23–1.38 (m, 2H) 0.83 (q, J = 12.0 Hz, 1H); ^{13}C -NMR (100.5 MHz, $CDCl_3$) δ (ppm) 145.6 (C) 141.0 (C) 128.0 (CH) 127.7 (CH) 126.7 (CH) 118.5 (CH) 63.7 (CH) 62.1 (CH) 48.5 (CH₂) 29.6 (CH₂) 27.7 (CH₂) 25.0 (CH₂) 20.9 (CH₂) 18.6 (CH₃); IR (neat) 3061, 3026, 2971, 2930, 2836, 2783, 2727, 2666, 1945, 1874, 1806, 1749, 1600 cm^{-1} ; HRMS (ES^+): calcd for $[C_{16}H_{22}N]^+$ 228.1752; found 228.1741. (**S***)-1-((**R***)-1-Phenylethyl)-2,3,5,6,7,7a-hexahydro-1H-indole (**2h**): R_f = 0.20 (EtOAc); 1H -NMR (400 MHz, $CDCl_3$) δ (ppm) 7.19–7.38 (m, 5H) 5.38 (bs, 1H) 4.06 (q, J = 7.0 Hz, 1H) 2.96–3.06 (m, 1H) 2.45–2.54 (m, 1H) 2.26–2.34 (m, 2H) 2.16–2.26 (m, 2H) 1.97–2.06 (m, 2H) 1.80–1.88 (m, 1H) 1.53 (d, J = 7.0 Hz, 3H) 1.40–1.50 (m, 1H) 1.13–1.23 (m, 1H); ^{13}C -NMR (100.5 MHz, $CDCl_3$) δ (ppm) 140.3 (C) 139.5 (C) 128.5 (CH) 127.6 (CH) 126.9 (CH) 118.5 (CH) 60.1 (CH) 57.7 (CH) 44.9 (CH₂) 28.5 (CH₂) 27.5 (CH₂) 25.2 (CH₂) 20.6 (CH₂) 19.8 (CH₃); IR (neat) 3083, 3060, 3026, 2972, 2931, 2858, 2836, 2783, 2727, 2666 cm^{-1} ; HRMS (ES^+): calcd for $[C_{16}H_{22}N]^+$ 228.1752; found 228.1745. Data obtained from mixture of both diastereoisomers.

(S)- and (R)-1-((R)-1-Phenylethyl)-1,2,3,4,6,7,8,8a-octahydroquinoline (2i)

Following the general procedure apart from conducting the second, cyclisation, step for 8 d. The two diastereoisomers were separated by flash column chromatography (EtOAc-cHex; 1:19) to give the *title compounds* as clear oils [Method A: 45%; (**R,R**)-**2i**: 24%, (**S,R**)-**2i**: 21%; Method B: 65%; (**R,R**)-**2i**: 32%, (**S,R**)-**2i**: 33%]. The relative stereochemistry was determined for the slower moving (**S,R**)-diastereoisomer by X-ray crystallography after formation of the hydrochloride salt and recrystallisation from CH_2Cl_2 . (**R**)-1-((**R**)-1-phenylethyl)-1,2,3,4,6,7,8,8a-octahydroquinoline (**2i**):^{3a} $[\alpha]_D^{25}$ = -46.1 (c 0.2, $CHCl_3$); R_f = 0.40 (EtOAc); 1H -NMR (400 MHz, $CDCl_3$) δ (ppm) 7.46 (d, J = 7.5 Hz, 2H) 7.29 (t, J = 7.5 Hz, 2H) 7.19 (t, J = 7.5 Hz, 1H) 5.48 (bs, 1H) 4.39 (q, J = 7.0 Hz, 1H) 3.04–3.10 (m, 1H) 2.43–2.51 (m, 1H) 2.13–2.25 (m, 3H) 1.91–2.10 (m, 3H) 1.78–1.86 (m, 1H) 1.44–1.60 (m, 3H) 1.29–1.38 (m, 1H) 1.28 (d, J = 7.0 Hz, 3H); ^{13}C -NMR (100.5 MHz, $CDCl_3$) δ (ppm) 144.7 (C) 137.7 (C) 127.9 (CH) 127.8 (CH) 126.1 (CH) 121.6 (CH) 57.6 (CH) 53.8 (CH) 45.1 (CH₂) 34.7 (CH₂) 29.0 (CH₂) 26.7 (CH₂) 25.5 (CH₂) 21.7 (CH₂) 7.7 (CH₃); IR (neat) 3085, 3059, 3028, 2929, 2855,

2837, 2795, 2750, 2717, 1947, 1875, 1805, 1710, 1672, 1601 cm^{-1} ; HRMS (ES^+): calcd for $[C_{17}H_{24}N]^+$ 242.1909; found 242.1903. (**S**)-1-((**R**)-1-Phenylethyl)-1,2,3,4,6,7,8,8a-octahydroquinoline (**2i**): $[\alpha]_D^{25}$ = +248 (c 0.2, $CHCl_3$); R_f = 0.20 (EtOAc); 1H -NMR (400 MHz, $CDCl_3$) δ (ppm) 7.33 (t, J = 7.5 Hz, 2H) 7.23–7.28 (m, 3H) 5.47 (bs, 1H) 4.41 (q, J = 7.0 Hz, 1H) 3.10–3.16 (m, 1H) 2.66–2.73 (m, 1H) 2.45–2.53 (m, 1H) 2.12–2.19 (m, 1H) 1.98–2.10 (m, 1H) 1.84–1.95 (m, 2H) 1.73–1.84 (m, 2H) 1.61–1.68 (m, 1H) 1.34–1.58 (m, 3H) 1.47 (d, J = 7.0 Hz, 3H); ^{13}C -NMR (100.5 MHz, $CDCl_3$) δ (ppm) 139.4 (C) 137.1 (C) 128.6 (CH) 127.7 (CH) 126.8 (CH) 122.7 (CH) 58.0 (CH) 55.0 (CH) 46.2 (CH₂) 34.6 (CH₂) 29.3 (CH₂) 26.9 (CH₂) 25.5 (CH₂) 21.7 (CH₂) 19.4 (CH₃); IR (neat) 3059, 3028, 2928, 2855, 2800, 2762, 2718, 1944, 1871, 1802, 1740, 1671, 1601; HRMS (ES^+): calcd for $[C_{17}H_{24}N]^+$ 242.1909; found 242.1899.

2R*-(1R*,2S*)-1,2-Dibromocyclohexyl)-N-(1-phenylethyl)-ethylamine and 2R*-(1S*,2R*)-1,2-dibromocyclohexyl)-N-(1-phenylethyl)ethylamine (3h)

2-Cyclohex-1-enyl-N-(1-phenylethyl)ethylamine **1h** (230 mg, 1.0 mmol, 1 equiv.) was dissolved in anhydrous CH_2Cl_2 (30 ml) and $NaHCO_3$ (168 mg, 2.0 mmol, 2 equiv.) added. The mixture was cooled to -78 °C. Br_2 (113 μ l, 2.2 mmol, 2.2 equiv.) was added as a solution in anhydrous CH_2Cl_2 (10 ml) in a dropwise fashion. The mixture was stirred for 10 min at -78 °C and subsequently slowly warmed to room temperature (approx. 1 h). The mixture was poured into a saturated Na_2SO_3 solution (20 ml) and was extracted with CH_2Cl_2 (3 $\times$ 40 ml). The combined organic layers were dried over $MgSO_4$, filtered and the solvent removed under reduced pressure. The crude material was directly subjected to flash column chromatography (EtOAc-cyclohexane; 1:9 to 3:7) and the *title compound* (162 mg, 42%) was isolated as a clear oil. R_f = 0.25 (EtOAc); 1H -NMR (400 MHz, $CDCl_3$) δ (ppm) 7.31–7.34 (m, 4H) 7.21–7.25 (m, 1H) 4.52–4.57 (bs/m, 1H) 3.82 (bq, J = 6.5 Hz, 1H) 2.74–2.87 (m, 2H) 2.45–2.55 (m, 1H) 2.08–2.29 (m, 2H) 1.90–2.04 (m, 2H) 1.76–1.89 (m, 3H) 1.70 (bs, 1H) 1.50–1.65 (m, 2H) 1.37 (d, J = 6.5 Hz, 3H); ^{13}C -NMR (100.5 MHz, $CDCl_3$) δ (ppm) 145.35 (C) 145.3 (C) 128.45 (CH) 128.4 (CH) 126.9 (CH) 126.5 (CH) 126.45 (CH) 74.25 (C) 74.2 (C) 59.5 (CH) 59.4 (CH) 58.3 (CH) 58.2 (CH) 45.1 (CH₂, broad) 43.35 (CH₂) 43.3 (CH₂) 35.85 (CH₂) 35.8 (CH₂) 31.75 (CH₂) 31.7 (CH₂) 24.4 (CH₃) 24.3 (CH₃) 22.05 (CH₂) 22.0 (CH₂) 20.4 (CH₂) 20.35 (CH₂).

N-Benzyl-2-((1R*,2S*)-1,2-dibromocyclohexyl)ethylamine (3a)

N-Benzyl-2-cyclohex-1-enylethylamine **1a** (215 mg, 1.0 mmol, 1 equiv.) was dissolved in anhydrous CH_2Cl_2 (30 ml) under an atmosphere of N_2 , $NaHCO_3$ (168 mg, 2.0 mmol, 2 equiv.) added in one portion and the solution cooled to -78 °C. Br_2 (113 μ l, 2.2 mmol, 2.2 equiv.) was added dropwise as a solution in anhydrous CH_2Cl_2 (10 ml). The mixture was stirred for 10 min. The cooling bath was then removed and the mixture slowly warmed to room temperature before pouring into a saturated $Na_2S_2O_3$ solution (20 ml). Extraction with CH_2Cl_2 (2 $\times$ 25 ml), drying of the combined organic layers over Na_2SO_4 , filtration and solvent removal under reduced pressure afforded the crude product. Immediate purification by flash column chromatography (EtOAc-cHex; 1:9) gave **3a** as a clear oil (48 mg, 13%). Note: the product

thus obtained was observed to undergo slow decomposition. R_f = 0.25 (EtOAc); $^1\text{H-NMR}$ (500 MHz, CDCl_3) δ (ppm) 7.25–7.39 (m, 5H) 4.64 (bs, 1H) 3.86 (s, 2H) 2.96–3.05 (m, 2H) 2.54–2.61 (m, 1H) 2.20–2.24 (m, 2H) 1.98–2.10 (m, 2H) 1.81–1.94 (m, 3H) 1.75 (bs, 1H) 1.57–1.70 (m, 2H); $^{13}\text{C-NMR}$ (125 MHz, CDCl_3) δ (ppm) 140.1 (C) 128.4 (CH) 128.1 (CH) 127.0 (CH) 74.3 (C) 59.5 (CH) 54.0 (CH_2) 45.1 (CH_2) 44.9 (CH_2) 35.9 (CH_2) 31.8 (CH_2) 22.1 (CH_2) 20.4 (CH_2); IR (neat) 3323, 3030, 2935, 2856, 1652, 1611 cm^{-1} ; HRMS (ES^+): calcd for $[\text{C}_{15}\text{H}_{22}\text{N}^{79}\text{Br}_2]^+$ 374.0119; found 374.0107.

General procedure for the synthesis of bromooctahydroindoles 9

The secondary cyclohex-1-enyl-amine **1** was dissolved in dichloromethane (5 ml/mmol). The solution was cooled to 0 °C and solid NBS (1 equiv.) was added in one portion. The mixture was stirred at 0 °C for 30 min, then warmed to room temperature over a period of 30 min and subsequently heated to reflux for 1 h. The volatiles were removed under reduced pressure and the residue suspended in pentane (5 ml/mmol), filtered through a sintered funnel, washed with pentane (2 × 5 ml/mmol) and the combined filtrates concentrated *in vacuo*. Flash column chromatography (EtOAc-cyclohexane; 1:19) gave the products as indicated below.

(3a*S**,7a*R*)-1-Benzyl-3a-bromooctahydroindole (9a)

The *title compound* **9a** (32%) was isolated as a viscous colourless oil. X-ray crystals of the corresponding HCl salt were formed from CH_2Cl_2 . R_f = 0.60 (EtOAc-cyclohexane; 1:4); $^1\text{H-NMR}$ (500 MHz, CDCl_3) δ (ppm) 7.28–7.33 (m, 4H) 7.21–7.26 (m, 1H) 4.05 (d, J = 13.5 Hz, 1H) 3.22 (d, J = 13.5 Hz, 1H) 2.92–2.98 (m, 1H) 2.86–2.89 (m, 1H) 2.33–2.42 (m, 2H) 2.08–2.18 (m, 2H) 1.95–2.01 (m, 1H) 1.84–1.91 (m, 1H) 1.75–1.81 (m, 1H) 1.58–1.69 (m, 2H) 1.51–1.58 (m, 1H) 1.37–1.43 (m, 1H); $^{13}\text{C-NMR}$ (125 MHz, CDCl_3) δ (ppm) 139.5 (C) 128.4 (CH) 128.2 (CH) 126.8 (CH) 69.4 (CH) 68.8 (C) 57.6 (CH_2) 50.6 (CH_2) 40.9 (CH_2) 38.7 (CH_2) 23.6 (CH_2) 23.1 (CH_2) 19.8 (CH_2); IR (neat) 3108, 3085, 3063, 3028, 2933, 2879, 2858, 2803, 1655, 1606, 1586, 1561 cm^{-1} ; HRMS (ES^+): calcd. for $[\text{C}_{15}\text{H}_{21}\text{N}^{79}\text{Br}]^+$ 294.0857; found 294.0865.

(3a*S**,7a*R**)-3a-Bromo-1-(4-methoxybenzyl)octahydroindole (9b)

The *title compound* **9b** (32%) was isolated as a viscous colourless oil. R_f = 0.50 (EtOAc-cyclohexane; 1:4); $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ (ppm) 7.21 (d, J = 8.5 Hz, 2H) 6.84 (d, J = 8.5 Hz, 2H) 3.96 (d, J = 13.0 Hz, 1H) 3.78 (s, 3H) 3.17 (d, J = 13.0 Hz, 1H) 2.89–2.96 (m, 1H) 2.82–2.87 (m, 1H) 2.29–2.43 (m, 2H) 2.04–2.18 (m, 2H) 1.93–2.02 (m, 1H) 1.74–1.87 (m, 2H) 1.48–1.69 (m, 3H) 1.32–1.46 (m, 1H); $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ (ppm) 158.5 (C) 131.4 (C) 129.5 (CH) 113.6 (CH) 69.3 (CH) 68.9 (C) 56.9 (CH_2) 55.2 (CH_3) 50.4 (CH_2) 40.9 (CH_2) 38.7 (CH_2) 23.6 (CH_2) 23.1 (CH_2) 19.8 (CH_2); IR (neat) 3061, 3031, 2996, 2933, 2858, 2833, 2806, 2727, 2685, 1668, 1612, 1586, 1512 cm^{-1} ; HRMS (ES^+): calcd. for $[\text{C}_{16}\text{H}_{23}\text{N}^{79}\text{BrO}]^+$ 324.0963; found 324.0974.

(3a*S**,7a*R**)-3a-Bromo-1-(2-bromo-4,5-dimethoxybenzyl)-octahydroindole (9d)

According to the procedure described **9d** (32%) was obtained as a viscous colourless oil. R_f = 0.40 (EtOAc-cHex; 1:4); $^1\text{H-NMR}$

(300 MHz, CDCl_3) δ (ppm) 7.05 (s, 1H) 6.98 (s, 1H) 3.91 (d, J = 14.0 Hz, 1H) 3.85 (s, 3H) 3.84 (s, 3H) 3.47 (d, J = 14.0 Hz, 1H) 2.96–3.03 (m, 2H) 2.52–2.60 (m, 1H) 2.35–2.45 (m, 1H) 2.15–2.24 (m, 1H) 1.99–2.11 (m, 2H) 1.80–1.91 (m, 1H) 1.47–1.73 (m, 4H) 1.34–1.43 (m, 1H); $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ (ppm) 148.4 (C) 148.3 (C) 130.7 (C) 115.4 (CH) 113.4 (C) 113.1 (CH) 69.7 (CH) 69.2 (C) 56.6 (CH_2) 56.1 (CH_3) 56.0 (CH_3) 50.8 (CH_2) 40.6 (CH_2) 38.8 (CH_2) 23.9 (CH_2) 23.1 (CH_2) 20.4 (CH_2); IR (neat) 3080, 2933, 2838, 2256, 1681, 1603 cm^{-1} ; HRMS (ES^+): calcd. for $[\text{C}_{17}\text{H}_{24}\text{N}^{79}\text{Br}_2\text{O}_2]^+$ 432.0174; found 432.0159.

N-Benzyl-N-chloro-2-cyclohex-1-enylethylamine (10a)

N-Benzyl-2-cyclohex-1-enylethylamine **1a** (215 mg, 1.0 mmol, 1 equiv.) was dissolved in CH_2Cl_2 (5 ml) and the solution cooled to 0 °C. Solid NCS (134 mg, 1.0 mmol, 1 equiv.) was added in one portion and the mixture stirred for 15 min. The solvent was removed under reduced pressure and the residue suspended in pentane (5 ml) and filtered through a sintered funnel. The solid was washed with pentane (2 × 5 ml) and the combined filtrate concentrated under reduced pressure. The crude product was immediately subjected to column chromatography (pentane-Et₂O; 9:1) to give **10a** (183 mg, 73%) as a clear oil. R_f = 0.70 (EtOAc); $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ (ppm) 7.30–7.42 (m, 5H) 5.48 (bs, 1H) 4.14 (s, 2H) 3.08 (t, J = 7.5 Hz, 2H) 2.38 (t, J = 7.5 Hz, 2H) 1.98–2.07 (m, 2H) 1.89–1.98 (m, 2H) 1.53–1.70 (m, 4H); $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ (ppm) 137.1 (C) 134.8 (C) 129.1 (CH) 128.3 (CH) 127.7 (CH) 122.6 (CH) 68.1 (CH_2) 61.9 (CH_2) 36.2 (CH_2) 28.8 (CH_2) 25.2 (CH_2) 22.9 (CH_2) 22.4 (CH_2); IR (neat) 3040, 2918, 2847, 2665, 1659, 1604 cm^{-1} ; HRMS (ES^+): calcd. for $[\text{C}_{15}\text{H}_{21}^{35}\text{ClN}]^+$ 250.1363; found 250.1351.

N-Chloro-2-cyclohex-1-enyl-N-(4-methoxybenzyl)ethylamine (10b)

As above, 2-cyclohex-1-enyl-N-(4-methoxybenzyl)ethylamine **1b** (245 mg, 1.0 mmol, 1 equiv.) was dissolved in CH_2Cl_2 (5 ml) cooled to 0 °C and solid NCS (134 mg, 1.0 mmol, 1 equiv.) added. After stirring for 15 min the solvent was removed and the residue suspended in pentane (10 ml). After filtration the resultant solid was washed with pentane (2 × 10 ml) and the combined filtrate concentrated under reduced pressure. The crude product was purified by flash column chromatography (pentane-Et₂O; 9:1) which gave **10b** (260 mg, 93%) as a clear oil. R_f = 0.75 (EtOAc); $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ (ppm) 7.25 (d, J = 8.5 Hz, 2H) 6.86 (d, J = 8.5 Hz, 2H) 5.43 (bs, 1H) 4.04 (s, 2H) 3.79 (s, 3H) 3.00 (t, J = 7.5 Hz, 2H) 2.32 (t, J = 7.5 Hz, 2H) 1.93–2.02 (m, 2H) 1.85–1.93 (m, 2H) 1.48–1.62 (m, 4H); $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ (ppm) 159.2 (C) 134.9 (C) 130.4 (CH) 129.2 (C) 122.5 (CH) 113.6 (CH) 67.5 (CH_2) 61.5 (CH_2) 55.2 (CH_3) 36.2 (CH_2) 28.5 (CH_2) 25.2 (CH_2) 22.9 (CH_2) 22.3 (CH_2); IR (neat) 3036, 2998, 2927, 2835, 1668, 1613, 1586, 1514 cm^{-1} ; HRMS (ES^+): calcd. for $[\text{C}_{16}\text{H}_{23}^{35}\text{ClNO}]^+$ 280.1468; found 280.1458.

2-Cyclohex-1-enyl-N-(4-methoxybenzyl)ethylammonium bromide (1b·HBr)

2-Cyclohex-1-enyl-N-(4-methoxybenzyl)ethylamine **1b** (245 mg, 1 mmol, 1 equiv.) was dissolved in Et₂O (5 ml) and the solution cooled to 0 °C. To the solution was added solid NBS (178 mg,

1 mmol, 1 equiv.) in one portion. The suspension was stirred for 30 min at room temperature before the solid was removed by filtration, which was washed with pentane (2 × 5 ml). The filtrate was immediately concentrated under reduced pressure to give *N*-bromo-2-cyclohex-1-enyl-*N*-(4-methoxybenzyl)ethylamine **5b** as a clear oil (324 mg, 100%). This *N*-halogenated species was directly subjected to NMR analysis. Due to the instability of the compound only a ¹H-NMR spectrum was obtained. ¹H-NMR (300 MHz, CDCl₃) δ (ppm) 7.25 (d, *J* = 8.5 Hz, 2H) 6.86 (d, *J* = 8.5 Hz, 2H) 5.43 (bs, 1H) 4.05 (s, 2H) 3.78 (s, 3H) 2.98 (t, *J* = 7.0 Hz, 2H) 2.32 (t, *J* = 7.0 Hz, 2H) 1.93–2.01 (m, 2H) 1.85–1.93 (m, 2H) 1.48–1.64 (m, 4H). A crystalline solid formed from CDCl₃ which was subjected to X-ray analysis and was identified as **1b·HBr** (yield not determined). M.pt. 148 °C (decomp.); ¹H-NMR (300 MHz, CDCl₃) δ (ppm) 9.11 (bs, 2H) 7.53 (d, *J* = 8.5 Hz, 2H) 6.91 (d, *J* = 8.5 Hz, 2H) 5.49 (bs, 1H) 4.04 (s, 2H) 3.76 (s, 3H) 2.88 (t, *J* = 8.0 Hz, 2H) 2.47 (t, *J* = 8.0 Hz, 2H) 1.92–2.01 (m, 2H) 1.77–1.85 (m, 2H) 1.47–1.62 (m, 4H); ¹³C-NMR (75 MHz, CDCl₃) δ (ppm) 160.5 (C) 132.1 (C) 132.0 (CH) 125.3 (CH) 121.6 (C) 114.5 (CH) 55.2 (CH₃) 50.0 (CH₂) 44.1 (CH₂) 33.9 (CH₂) 28.0 (CH₂) 25.2 (CH₂) 22.6 (CH₂) 22.0 (CH₂); IR (CH₂Cl₂) 3433, 2929, 2795, 2700, 2396, 1613, 1516 cm⁻¹; Anal. Calcd. for C₁₆H₂₄BrNO: C (58.90) H (7.41) N (4.29) Br (24.49), Found: C (58.61) H (7.20) N (4.26) Br (24.37).

N-Benzyl-2-((1*R**,2*S**)-1,2-dibromocyclohexyl)ethylammonium bromide (**3a·HBr**)

N-Benzyl-2-cyclohex-1-enylethylamine **1a** (46 mg, 0.21 mmol, 1 equiv.) was dissolved in CDCl₃ (2 ml). PHT (106 mg, 0.21 mmol, 1 equiv.) was added in one portion and the mixture stirred for 15 min. Complete conversion was observed by NMR spectroscopy and the title compound was characterized as its HBr salt. ¹H-NMR (600 MHz, CDCl₃) δ (ppm) 9.74 (bs, 2H) 7.57–7.59 (m, 2H) 7.32–7.38 (m, 3H) 4.38 (s, 1H) 4.16 (t, *J* = 5.5 Hz, 2H) 3.15–3.27 (m, 2H) 2.53–2.63 (m, 2H) 2.40–2.46 (m, 1H) 1.98–2.02 (m, 1H) 1.89–1.94 (m, 1H) 1.82–1.86 (m, 1H) 1.70–1.78 (m, 2H) 1.59–1.65 (m, 1H) 1.48–1.55 (m, 1H); ¹³C-NMR (150 MHz, CDCl₃) δ (ppm) 130.2 (CH) 129.9 (C) 129.4 (CH) 129.0 (CH) 71.3 (C) 58.4 (CH) 50.5 (CH₂) 42.6 (CH₂) 39.7 (CH₂) 35.5 (CH₂) 31.5 (CH₂) 21.8 (CH₂) 20.3 (CH₂); HRMS (ES⁺): calcd. for [C₁₅H₂₂N⁷⁹Br₂]⁺ 374.0119; found 374.0104.

(3*aR**,7*aR**)-1-(Toluene-4-sulfonyl)octahydroindole (**12a**)¹⁸

1-Benzyl-2,3,5,6,7,7a-hexahydro-1*H*-indole **2a** (107 mg, 0.5 mmol, 1 equiv.) was dissolved in glacial acetic acid (10 ml) and the solution degassed for 30 min with a steady stream of N₂. Pd/C (10% Pd on carbon, w/w, 53 mg, 0.05 mmol, 0.1 equiv.) was added and the flask purged with H₂ and subsequently equipped with a H₂ balloon. The reaction mixture was stirred for 24 h at room temperature. Filtration through celite and washing with glacial acetic acid (2 × 10 ml) followed by concentration of the combined filtrates under reduced pressure gave the crude secondary amine. The residue was dissolved in CH₂Cl₂ (10 ml) and K₂CO₃ (691 mg, 5 mmol, 10 equiv.) added. The suspension was cooled to 0 °C before TsCl (95 mg, 0.5 mmol, 1 equiv.) was added in one portion. The mixture was stirred at 0 °C for 1 h followed by 6 h at room temperature. The mixture was poured

into H₂O (10 ml) and the aqueous layer was acidified using 1 M HCl (pH ~ 2). The aqueous layer was extracted with CH₂Cl₂ (2 × 10 ml) and the combined organic layers were washed with brine (10 ml), dried over MgSO₄, filtered and the solvent removed under reduced pressure. The crude material was subjected to flash column chromatography (EtOAc-cyclohexane; 1:19) which gave **12a** (103 mg, 74%) as a colourless solid. X-ray quality crystals were obtained by slow evaporation from EtOH. M.pt. 50–52 °C (EtOH); *R*_f = 0.25 (EtOAc-cyclohexane; 1:9); ¹H-NMR (500 MHz, CDCl₃) δ (ppm) 7.71 (d, *J* = 8.0 Hz, 2H) 7.30 (d, *J* = 8.0 Hz, 2H) 3.48–3.56 (m, 2H) 3.18 (q, *J* = 9.0 Hz, 1H) 2.42 (s, 3H) 1.76–1.92 (m, 3H) 1.49–1.65 (m, 5H) 1.29–1.41 (m, 2H) 1.17–1.27 (m, 1H); ¹³C-NMR (125.6 MHz, CDCl₃) δ (ppm) 142.9 (C) 135.3 (C) 129.5 (CH) 127.2 (CH) 59.5 (CH) 47.2 (CH₂) 37.7 (CH) 29.8 (CH₂) 27.6 (CH₂) 26.2 (CH₂) 23.1 (CH₂) 21.4 (CH₃) 21.3 (CH₂); IR (CH₂Cl₂) 3625, 3549, 3064, 3029, 2929, 2859, 1922, 1813, 1598, 1339, 1161 cm⁻¹; HRMS (ES⁺): calcd. for [C₁₅H₂₂NO₂S]⁺ 280.1371; found 280.1368.

(4*aR**,8*aR**)- and (4*aS**,8*aR**)-1-(Toluene-4-sulfonyl)-decahydroquinoline (**12g**)

As above, a mixture of 1-benzyl-1,2,3,4,6,7,8,8a-octahydroquinoline **2g** (70 mg, 0.31 mmol, 1 equiv.), Pd/C (10% Pd on carbon, w/w, 33 mg, 0.031 mmol, 0.1 equiv.) in glacial acetic acid (6 ml) was stirred under an atmosphere of H₂ (1 atm.) at room temperature for 24 h. The crude amine was dissolved in CH₂Cl₂ (6 ml) and TsCl (65 mg, 0.34 mmol, 1.1 equiv.) and K₂CO₃ (428 mg, 3.1 mmol, 10 equiv.) were added. The suspension was stirred for 14 h at room temperature. Work up as above gave the crude product which was subjected to column chromatography (cyclohexane-EtOAc; 19:1) to give **12g** (44 mg, 48%)—approximately a 1:1 mixture of *cis* and *trans* diastereoisomers as a clear oil. *R*_f = 0.30 (EtOAc-cyclohexane; 1:9); ¹H-NMR (400 MHz, CDCl₃) δ (ppm) 7.64–7.73 (m, 4H) 7.22–7.31 (m, 4H) 4.03–4.12 (m, 1H) 3.92–4.02 (m, 1H) 3.65–3.73 (m, 1H) 2.91 (t, *J* = 13.0 Hz, 1H) 2.69–2.79 (m, 1H) 2.42–2.50 (m, 1H) 2.41 (s, 6H) 2.21–2.29 (m, 1H) 1.48–1.80 (m, 14H) 1.07–1.47 (m, 9H) 0.87–1.02 (m, 2H); ¹³C-NMR (100.5 MHz, CDCl₃) δ (ppm) 142.8 (C) 142.6 (C) 139.0 (C) 137.9 (C) 129.6 (CH) 129.5 (CH) 127.1 (CH) 126.9 (CH) 65.1 (CH) 55.3 (CH) 48.6 (CH₂) 41.1 (CH) 40.3 (CH₂) 35.0 (CH) 33.5 (CH₂) 31.8 (CH₂) 31.7 (CH₂) 31.6 (CH₂) 26.0 (CH₂) 25.6 (CH₂) 25.5 (CH₂) 25.4 (CH₂) 25.3 (CH₂) 24.0 (CH₂) 23.5 (CH₂) 21.5 (CH₃, 2x) 20.0 (CH₂); IR (neat) 3064, 3028, 2927, 2855, 1920, 1689, 1656, 1599, 1337, 1323, 1169, 1152 cm⁻¹; HRMS (ES⁺): calcd. for [C₁₆H₂₄NO₂S]⁺ 294.1528; found 294.1541.

(3*aS**,7*aR**)-3a-Bromo-1-(toluene-4-sulfonyl)octahydroindole (**13**)

As above, *rac*-(3*aS*,7*aR*)-1-benzyl-3a-bromooctahydro-1*H*-indole **9a** (200 mg, 0.68 mmol, 1 equiv.) and Pd/C (10% Pd on carbon, w/w, 72 mg, 0.068 mmol, 0.1 equiv.) in glacial acetic acid (13 ml) was stirred under H₂ (1 atm.) for 13.5 h at room temperature. The crude amine was dissolved in CH₂Cl₂ (7 ml) and treated with triethylamine (105 μl, 0.75 mmol, 1.1 equiv.) and TsCl (129 mg, 0.68 mmol, 1 equiv.). After work up as detailed above the crude product was purified by column chromatography (EtOAc-cyclohexane; 1:19). Thus, the *title compound* (55 mg, 23%) was obtained as a white gum. *R*_f = 0.25 (EtOAc-cyclohexane; 1:4);

¹H-NMR (500 MHz, CDCl₃) δ (ppm) 7.75 (d, *J* = 8.0 Hz, 2H) 7.30 (d, *J* = 8.0 Hz, 2H) 3.84 (dd, *J* = 6.5, 10.0 Hz, 1H) 3.65 (dt, *J* = 2.0, 9.5 Hz, 1H) 3.47 (dt, *J* = 7.5, 9.5 Hz, 1H) 2.43–2.49 (m, 1H) 2.41 (s, 3H) 2.36–2.41 (m, 1H) 2.20–2.30 (m, 2H) 2.04 (dd, *J* = 7.0, 14.0 Hz, 1H) 1.67–1.75 (m, 1H) 1.49–1.60 (m, 2H) 1.28–1.39 (m, 2H); ¹³C-NMR (125.6 MHz, CDCl₃) δ (ppm) 143.2 (C) 134.7 (C) 129.4 (CH) 127.7 (CH) 71.4 (C) 68.4 (CH) 46.2 (CH₂) 39.5 (CH₂) 37.8 (CH₂) 33.7 (CH₂) 23.7 (CH₂) 22.8 (CH₂) 21.5 (CH₃); IR (CH₂Cl₂) 3030, 2940, 2890, 2863, 1642, 1599, 1343, 1160, 667 cm⁻¹; HRMS (ES⁺): calcd. for [C₁₅H₂₁⁷⁹BrNO₂S]⁺ 358.0476; found 358.0473.

Acknowledgements

We thank Dr Dilip Rai for high resolution mass spectra and Dr. Yannick Ortin for assistance with NMR spectra.

References

- 1 T. M. Müller, K. C. Hultsch, M. Yus, F. Foubelo and M. Tasa, *Chem. Rev.*, 2008, **108**, 3795.
- 2 (a) For examples see: D. E. Horning and J. M. Muchowski, *Can. J. Chem.*, 1974, **52**, 1321; (b) F. Diaba, E. Ricou and J. Bonjoch, *Org. Lett.*, 2007, **9**, 2633; (c) K. C. Majumdar, U. K. Kundu, U. Das, N. K. Jana and B. Roy, *Can. J. Chem.*, 2005, **83**, 63; (d) W. S. Lee, K. C. Jang, J. H. Kim and K. H. Park, *Chem. Commun.*, 1999, 251; (e) A. D. Jones, D. W. Knight and D. E. Hibbs, *J. Chem. Soc., Perkin Trans. 1*, 2001, 1182; (f) H. Fujioka, K. Murai, Y. Ohba, H. Hirose and Y. Kita, *Chem. Commun.*, 2006, 832; (g) R. R. Gataullin, N. A. Likhacheva and I. B. Abdrakhmanov, *Russ. J. Org. Chem.*, 2007, **43**, 409; (h) M. C. Marcotullio, V. Campagna, S. Sternativo, F. Costantino and M. Curini, *Synthesis*, 2006, 2760; (i) R. Fan, F. Wen, L. Qin, D. Pu and B. Wang, *Tetrahedron Lett.*, 2007, **48**, 7444; (j) A. Lei, X. Lu and G. Liu, *Tetrahedron Lett.*, 2004, **45**, 1785; (k) M. R. Manzoni, T. P. Zabawa, D. Kasi and S. R. Chemler, *Organometallics*, 2004, **23**, 5618; (l) M. Hemmerling, Å. Sjöholm and P. Somfai, *Tetrahedron: Asymm.*, 1999, **10**, 4091; (m) J. Cossy, L. Tresnard and D. G. Pardo, *Tetrahedron Lett.*, 1999, **40**, 1125; (n) H. Senboku, Y. Kajizuka, H. Hasegawa, H. Fujita, H. Sugimoto, K. Orito and M. Tokuda, *Tetrahedron Lett.*, 1999, **55**, 6465; (o) E. J. Corey, C. -P. Chen and G. A. Reichard, *Tetrahedron Lett.*, 1989, **30**, 5547; (p) R. Askani, T. Andermann and K. M. Müller, *Chem. Ber.*, 1992, **125**, 1927; (q) R. Göttlich, *Synthesis*, 2000, 1561.
- 3 (a) Z. Shao, J. Chen, Y. Tu, L. Li and H. Zhang, *Chem. Commun.*, 2003, 1918; (b) Z. Shao, F. Peng, B. Zhu, Y. Tu and H. Zhang, *Chin. J. Chem.*, 2004, **22**, 727; (c) Z. Shao, F. Peng, J. Chen, C. Wang, R. Huang, Y. Tu, L. Li and H. Zhang, *Synth. Commun.*, 2004, **34**, 2031.
- 4 (a) For examples of S_N2 processes related to this conversion see: M. D. Middleton and S. T. Diver, *Tetrahedron Lett.*, 2005, **46**, 4039; (b) M. D. Middleton, B. P. Peppers and S. T. Diver, *Tetrahedron*, 2006, **62**, 10528.
- 5 B. R. Cho, S. K. Namgoong and T. R. Kim, *J. Chem. Soc., Perkin Trans. 2*, 1987, 853.
- 6 E. J. Corey, J. F. Arnett and G. N. Widinger, *J. Am. Chem. Soc.*, 1975, **97**, 430.
- 7 (a) For examples see: P. L. Southwick and V. L. Walsh, *J. Am. Chem. Soc.*, 1955, **77**, 405; (b) G. Berti and A. Marsili, *Tetrahedron*, 1966, **22**, 2977; (c) N. G. Ramesh, E. H. Heijne, A. J. H. Klunder and B. Zwanenburg, *Tetrahedron*, 2002, **58**, 1361.
- 8 (a) E. Erdik and M. Ay, *Chem. Rev.*, 1989, **89**, 1947; (b) H. Wack, A. E. Taggi, A. M. Hafez, W. J. Drury, III and T. Lectka, *J. Am. Chem. Soc.*, 2001, **123**, 1531; (c) S. P. Bew, D. L. Hughes, N. J. Palmer, V. Savic, K. M. Soapi and M. A. Wilson, *Chem. Commun.*, 2006, 4338; (d) A. C. Smith and R. M. Williams, *Angew. Chem., Int. Ed.*, 2008, **47**, 1736.
- 9 D. St, C. Black and J. E. Doyle, *Aus. J. Chem.*, 1978, **31**, 2247.
- 10 Y. Yokoyama, T. Yamaguchi, M. Sato, E. Kobayashi and Y. Murakami, *Chem. Pharm. Bull.*, 2006, **54**, 1715.
- 11 (a) D. V. C. Awang and S. Wolfe, *Can. J. Chem.*, 1969, **47**, 706; (b) W. E. Daniels, M. E. Chiddix and S. A. Glickman, *J. Org. Chem.*, 1963, **28**, 573.
- 12 Compound **2h**-HCl; Molecular formula: C₁₆H₂₂ClN·H₂O; Formula weight: 281.81 g mol⁻¹; Crystal system: Monoclinic; Unit cell dimensions: a = 10.3845(9) Å, α = 90°; b = 14.8703(13) Å, β = 107.902(2)°; c = 10.5114(9) Å, γ = 90°; Volume: 1544.6(2) Å³; Temperature: 293(2) K; Space group: P2₁/n; Number of formula units in unit cell (Z): 4; Reflections collected: 26250; Independent reflections: 3029 [R(int) = 0.0178]; Final R indices [I > 2σ(I)]: R1 = 0.0501, wR2 = 0.1499; R indices (all data): R1 = 0.0533, wR2 = 0.1540.
- 13 Compound **2i**-HCl; Molecular formula: C₁₇H₂₄NCl; Formula weight: 277.82 g mol⁻¹; Crystal system: Monoclinic; Unit cell dimensions: a = 16.115(2) Å, α = 90°; b = 10.4898(13) Å, β = 121.095(3)°; c = 10.9685(14) Å, γ = 90°; Volume: 1587.7(4) Å³; Temperature: 293(2) K; Space group: C2; Number of formula units in unit cell (Z): 4; Reflections collected: 4287; Independent reflections: 1664 [R(int) = 0.0327]; Final R indices [I > 2σ(I)]: R1 = 0.0432, wR2 = 0.1006; R indices (all data): R1 = 0.0517, wR2 = 0.1045; Flack parameter: -0.02(10).
- 14 Compound **9a**-HCl; Molecular formula: C₁₅H₂₁NCIBr; Formula weight: 330.69 g mol⁻¹; Crystal system: Monoclinic; Unit cell dimensions: a = 26.387(5) Å, α = 90°; b = 6.8937(12) Å, β = 122.455(3)°; c = 19.161(3) Å, γ = 90°; Volume: 2941.0(9) Å³; Temperature: 100(2) K; Space group: C2/c; Number of formula units in unit cell (Z): 8; Reflections collected: 28702; Independent reflections: 3626 [R(int) = 0.0271]; Final R indices [I > 2σ(I)]: R1 = 0.0267, wR2 = 0.0686; R indices (all data): R1 = 0.0297, wR2 = 0.0700.
- 15 M. Noack, S. Kalsow and R. Göttlich, *Synlett*, 2004, 1110.
- 16 P. Wipf and J.-L. Methot, *Org. Lett.*, 2000, **2**, 4213.
- 17 Compound **12a**; Molecular formula: C₁₅H₂₁NO₂S; Formula weight: 279.39 g mol⁻¹; Crystal system: Orthorhombic; Unit cell dimensions: a = 6.237(2) Å, α = 90°; b = 12.419(4) Å, β = 90°; c = 17.923(6) Å, γ = 90°; Volume: 1388.2(8) Å³; Temperature: 100(2) K; Space group: P2₁2₁2₁; Number of formula units in unit cell (Z): 4; Reflections collected: 5752; Independent reflections: 1710 [R(int) = 0.0877]; Final R indices [I > 2σ(I)]: R1 = 0.0554, wR2 = 0.1326; R indices (all data): R1 = 0.0640, wR2 = 0.1371.
- 18 (a) M. R. Maderdos, L. H. Schader, D. D. Sprengel and J. L. Wood, *Org. Lett.*, 2007, **9**, 4427; (b) U. M. Rai and A. Hassner, *Heterocycles*, 1990, **30**, 817.